Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. doi: 10.1016/j.jacc.2008.02.034.
No abstract available

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Apolipoprotein B-100 / blood
  • Arteriosclerosis / blood
  • Arteriosclerosis / physiopathology
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / physiopathology*
  • Cardiovascular Diseases / prevention & control
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Lipoproteins / blood*
  • Risk Assessment
  • Risk Factors
  • Societies, Medical
  • Triglycerides / blood
  • United States

Substances

  • Apolipoprotein B-100
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins
  • Triglycerides